<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">15460184</PMID>
      <DateCompleted>
        <Year>2004</Year>
        <Month>12</Month>
        <Day>02</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>09</Month>
        <Day>17</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0277-0008</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>24</Volume>
            <Issue>9</Issue>
            <PubDate>
              <Year>2004</Year>
              <Month>Sep</Month>
            </PubDate>
          </JournalIssue>
          <Title>Pharmacotherapy</Title>
          <ISOAbbreviation>Pharmacotherapy</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Enterococcus faecalis resistant to linezolid: case series and review of the literature.</ArticleTitle>
        <Pagination>
          <StartPage>1225</StartPage>
          <EndPage>1231</EndPage>
          <MedlinePgn>1225-31</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Reports of linezolid resistance among Enterococcus faecalis have been relatively rare. We describe three patients with linezolid-resistant strains of E. faecalis, discovered after the patients had received long courses (&gt; 30 days) of linezolid therapy. All strains contained the G2576U mutation in 23S rRNA. A literature review revealed one other case in the United States and three cases in Europe; all involved patients who had received long courses of therapy. It appears that recent or extended linezolid therapy may be a risk factor for development of resistant E. faecalis. In patients who have recently been treated with linezolid and have an identified new systemic enterococcal isolate, linezolid sensitivity should be verified as soon as possible to guide therapy. This strategy also should be considered for patients with a breakthrough enterococcal isolate during linezolid therapy.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Burleson</LastName>
            <ForeName>Brian S</ForeName>
            <Initials>BS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy Practice, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, Texas, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ritchie</LastName>
            <ForeName>David J</ForeName>
            <Initials>DJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Micek</LastName>
            <ForeName>Scott T</ForeName>
            <Initials>ST</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dunne</LastName>
            <ForeName>W Michael</ForeName>
            <Initials>WM</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Pharmacotherapy</MedlineTA>
        <NlmUniqueID>8111305</NlmUniqueID>
        <ISSNLinking>0277-0008</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000081">Acetamides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000890">Anti-Infective Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D023303">Oxazolidinones</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>ISQ9I6J12J</RegistryNumber>
          <NameOfSubstance UI="D000069349">Linezolid</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000081" MajorTopicYN="N">Acetamides</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000890" MajorTopicYN="N">Anti-Infective Agents</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D024901" MajorTopicYN="Y">Drug Resistance, Multiple, Bacterial</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013293" MajorTopicYN="N">Enterococcus faecalis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016908" MajorTopicYN="N">Gram-Positive Bacterial Infections</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069349" MajorTopicYN="N">Linezolid</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008826" MajorTopicYN="N">Microbial Sensitivity Tests</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023303" MajorTopicYN="N">Oxazolidinones</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <NumberOfReferences>34</NumberOfReferences>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2004</Year>
          <Month>10</Month>
          <Day>6</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2004</Year>
          <Month>12</Month>
          <Day>16</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2004</Year>
          <Month>10</Month>
          <Day>6</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">15460184</ArticleId>
        <ArticleId IdType="doi">10.1592/phco.24.13.1225.38086</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
